Free tool
FAERS Monitor: Defencath
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214520 or its brand name (Defencath, Heparin Sodium, Taurolidine). Reports on generic versions are filed under their own applications.
Reports
10
Serious
4
40% of reports
Hospitalization
3
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device malfunction4
- drug hypersensitivity3
- complication associated with device1
- device occlusion1
- dialysis1
- drug ineffective1
- fall1
- hypoxia1
- infusion related reaction1
- mental status changes1
- occupational exposure to product1
- panic attack1
- paraesthesia oral1
- product container issue1
- product package associated injury1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product package associated injury | 1 | 944.1 | 147.0 | 235 |
| occupational exposure to product | 1 | 327.2 | 51.0 | 81 |
| product container issue | 1 | 245.4 | 38.2 | 60 |
| device occlusion | 1 | 149.5 | 23.3 | 36 |
| dialysis | 1 | 148.2 | 23.1 | 36 |
| paraesthesia oral | 1 | 145.8 | 22.7 | 35 |
| complication associated with device | 1 | 144.9 | 22.6 | 35 |
| device malfunctionSignal | 4 | 119.7 | 56.0 | 361 |
| mental status changes | 1 | 75.8 | 11.8 | 18 |
| hypoxia | 1 | 59.7 | 9.3 | 14 |
| panic attack | 1 | 57.7 | 9.0 | 13 |
| drug hypersensitivitySignal | 3 | 32.6 | 12.7 | 64 |
| infusion related reaction | 1 | 31.7 | 4.9 | 7 |
| fall | 1 | 6.3 | 1.0 | 1 |
| drug ineffective | 1 | 1.6 | 0.2 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.